Dr. Amgad M. Rabie PhD
Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Tanta University ORCID: 0000-0003-3681-114X · Egypt
Editorial leadership for International Journal of Coronaviruses ISSN 2692-1537
Research interests
- Medicinal Chemistry Drug Design
- Discovery Anticancer Drug Development Antimicrobial
- Antiviral Agents Heterocyclic Chemistry Computational Chemistry & Molecular Modeling Green Chemistry In Organic Synthesis Structure-Activity Relationship (Sar) Studies Admet Prediction
Biography
Dr. Amgad M. Rabie is a distinguished academic and researcher serving as an Associate Professor in the Department of Pharmaceutical Medicinal Chemistry at Tanta University, Egypt. His work is primarily focused on the frontier of drug discovery and development, with a specialization in the design, synthesis, and biological evaluation of novel heterocyclic compounds. Dr. Rabie's research program strategically targets the creation of potent therapeutic agents to combat pressing global health challenges, including cancer, microbial infections, and viral diseases. He integrates sophisticated computational chemistry methodologies, such as molecular docking, pharmacophore modeling, and ADMET prediction, to rationalize drug design and optimize lead compounds. His scholarly contributions are significant, demonstrated by a prolific publication record in high-impact international journals. Dr. Rabie is dedicated to advancing the field of medicinal chemistry through innovative research and the mentorship of future pharmaceutical scientists.
Education Details
- PhD in Pharmaceutical Medicinal Chemistry, Tanta University, Egypt (2015)
- M.Sc. in Pharmaceutical Medicinal Chemistry, Tanta University, Egypt (2012)
- B.Sc. in Pharmaceutical Sciences, Tanta University, Egypt (2007)
Professional Background
- Associate Professor, Department of Pharmaceutical Medicinal Chemistry, Tanta University (2020–Present)
- Lecturer (Assistant Professor), Department of Pharmaceutical Medicinal Chemistry, Tanta University (2015–2020)
- Assistant Lecturer, Department of Pharmaceutical Medicinal Chemistry, Tanta University (2012–2015)
- Demonstrator, Department of Pharmaceutical Medicinal Chemistry, Tanta University (2008–2012)
Achievements
- Recipient of the Tanta University Encouragement Award for Medical Sciences (2020)
Current Research Projects
- His current research focuses on the development of multi-target anticancer agents by designing hybrid molecules that act on key signaling pathways like EGFR and VEGFR. He is also exploring novel scaffolds for potent antibacterial and antifungal agents to combat drug-resistant strains. A significant part of his work involves using green chemistry principles for the eco-friendly synthesis of these bioactive compounds.
Academic Profiles of Dr. Amgad M. Rabie
Selected publications
- Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication 2022 cited 128×
- Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs 2021 cited 88×
- Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19 2021 cited 73×
- Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species 2023 cited 66×
- Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies 2022 cited 60×
- Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease 2022 cited 58×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering IJCV for your work?
This journal is guided by Dr. Amgad M. Rabie (Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Tanta University ORCID: 0000-0003-3681-114X) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.